Our Team: Driven & Diverse

Ryan Cohlhepp, Pharm.D.

• Leading biotech executive with over 20 years of expertise in driving early-stage drug development to commercial success
• Founding executive of Rheos Medicines, an immuno-metabolism company launched from Third Rock Ventures
• Responsible for Takeda’s commercial oncology portfolio in the US that included four compounds across a range of both hematological and solid tumors
• Pharm.D. in Pharmacy from Purdue University and current member of the Dean’s Advisory Council

F. Stephen Hodi, M.D.

Vijay Kuchroo, D.V.M., Ph.D.

• Institute Member, Broad Institute of MIT and Harvard
• Inventor on 25 patents, founder of five biotech companies, and member of numerous scientific advisory boards, including those of Biocon, Pfizer, Novartis and GSK
• Founding Director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women’s Hospital and the Kuchroo Laboratory, a leader in research that created the basis for describing the TIM family of genes
• Ph.D. in Pathology from the University of Queensland, Brisbane Australia; bachelor’s degree from the College of Veterinary Medicine, Hisar, India

Nils Lonberg, Ph.D.

• Three decades of experience in the biotech and pharma industries, focused on platform innovation, drug discovery and drug development
• A leader in the use of genetically engineered mice for antibody drug discovery, resulting in multiple FDA-approved antibody products; conducted substantial research involving transgenic mice in order to discover new medicines that could be effective for humans
• Currently an Executive in Residence at Canaan Partners, an early-stage venture capital firm; previously served as Senior Vice President of Biologics Discovery and led oncology discovery at Bristol-Myers Squibb
• Ph.D. in Biochemistry and Molecular Biology from Harvard University

Claire Mazumdar, Ph.D., MBA

• Business development and corporate strategy at Rheos Medicines, a biopharmaceutical company in Cambridge, Massachusetts, where she supported a major partnership with Roche
• Senior Associate at Third Rock Ventures, focused on company formation and supporting business development for portfolio companies
• Ph.D. in Cancer Biology from Stanford Medical School and MBA from Stanford University Graduate School of Business; bachelor’s degree in biological engineering from MIT

Kiran Mazumdar-Shaw

• Pioneering biotech entrepreneur who founded and runs Biocon, India’s leading biotechnology enterprise
• Committed to innovation and affordability in delivering top-of-the-line therapeutics to patients around the world
• Named as one of TIME magazine’s 100 most influential people in the world for her work in the biotech space and her experience as a leader in business
• Master’s degree from the University of Melbourne; bachelor’s degree in Zoology and Animal Biology from Bangalore University

Chaitanya Divgi, MBBS

• Nuclear medicine physician-scientist with more than 30 years of experience in top institutions leading programs in nuclear oncology imaging and therapy
• Has held positions at Memorial Sloan Kettering Cancer Center, University of Pennsylvania and Columbia University

Thomas F. Gajewski, M.D., Ph.D.

• AbbVie Foundation Professor of Cancer Immunotherapy and Professor in both the Ben May Department for Cancer Research and the Department of Pathology at the University of Chicago
• Investigates and develops new treatments for patients with melanoma and in the development of immunotherapies against this disease
• Leads the development of immune-based therapies for cancers other than melanoma, using new laboratory data on how the immune system is regulated to develop novel clinical trials

Caetano Reis e Sousa, D.Phil

• Senior group leader and assistant research director at the Crick and head of the Immunobiology Laboratory
• Professor of Immunology in the Department of Medicine at Imperial College London
• Holds honorary professorships at both University College London (UCL) and King’s College London

Arlene Sharpe, M.D., Ph.D.

• George Fabyan Professor of Comparative Pathology and Chair of the Department of Immunology at Harvard Medical School
• Member of the Department of Pathology at Brigham and Women’s Hospital, a Member at the Broad Institute of MIT and Harvard, Leader of the Cancer Immunology Program at the Dana-Farber/Harvard Cancer Center, and Co-Director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women’s Hospital
• Heads laboratory that discovered and elucidated the functions of T cell costimulatory pathways, including the immunoinhibitory functions of the CTLA-4 and PD-1 pathways, which have become exceptionally promising targets for cancer immunotherapy

Dario Vignali, Ph.D.

• Frank Dixon Chair in Cancer Immunology, Vice Chair and Professor of Immunology at University of Pittsburgh School of Medicine
• Director of Cancer Immunology Training Program, Co-Leader of the Cancer Immunology Program, Co-Director of the Tumor Microenvironment Center at University of Pittsburgh Cancer Institute (UPCI)
• Leads Vignali Laboratory at University of Pittsburgh

Jedd D. Wolchok, M.D., Ph.D., FASCO

• Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation; Chief, Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
• Director, Parker Institute for Cancer Immunotherapy Associate Director, Ludwig Center for Cancer Immunotherapy; Member, Ludwig Cancer Research, Memorial Sloan Kettering Cancer Center
• Professor of Medicine, Weill Medical College of Cornell University